Companies Flocking to Japan for Biotech Deals: CJ Partners' Colin Lee Novick

For the last two years, Japan has been at the forefront of accelerated approval for regenerative medicine products and has seen lots of licensing and contract manufacturing deals and M&A activity. For The Life Sciences Report Tokyo-based Colin Lee Novick, Managing Director of CJ PARTNERS, surveys the landscape, discussing recent tie-ups, the effects of the recently passed 21st Century Cures Act in the U.S., and what may lie ahead.

View the full transcript via The Life Sciences Report here.


Regeneus receives cash payment from Japan partner

The strategic collaboration and licensing agreement recently entered into is for the manufacture, clinical development and commercialisation of Progenza in Japan.

Progenza is a patented off-the-shelf stem cell technology developed for the treatment of knee osteoarthritis and other inflammatory conditions.

Read the full article by Proactive Investors here.


Regeneus enters 2017 backed by transformational Japan deal

Regeneus (ASX:RGS) has a busy 2017 to come, spearheaded by its recent entry into the Japanese market for its Progenza product.

The company entered into a strategic collaboration and licensing agreement for the manufacture, clinical development and commercialisation of Progenza in Japan.

Read the full article by Proactive Investors here.


Regeneus Q4 2016 News Update

Regeneus released our Q4 2016 update newsletter designed to keep our investors and followers of the company up to date with all the company and industry news over the last quarter.

Read our Q4 2017 newsletter here.